Cencora details $111.3M insurance-funded derivative settlement

Cencora, Inc. reported that it has reached an agreement, subject to court approval, to resolve a stockholder derivative lawsuit in the Delaware Court of Chancery.

Rhea-AI Filing Summary

Cencora, Inc. reported that it has reached an agreement, subject to court approval, to resolve a stockholder derivative lawsuit in the Delaware Court of Chancery. The case, brought by Lebanon County Employees’ Retirement Fund and Teamsters Local 443 Health Services & Insurance Plan, alleges breaches of fiduciary duty related to oversight of the company’s controlled substance diversion control programs.

Under a Stipulation and Agreement of Settlement filed on August 15, 2025, insurance carriers would pay the company $111.3 million, less any attorneys’ fees and litigation expenses awarded by the Court to the plaintiffs’ counsel, if the Court approves the settlement. The defendants do not admit liability and expressly deny any wrongdoing. The Court has entered a scheduling order and directed the company to file this report, attach the settlement documents, and post them in its investor relations website.

Insights

Litigation and governance analyst

Cencora moves to settle a derivative suit with a $111.3M insurance-funded recovery, pending court approval.

The company describes a proposed settlement of a Delaware stockholder derivative action alleging fiduciary duty breaches tied to oversight of controlled substance diversion control programs. A Special Litigation Committee led the investigation and, after mediation, the parties agreed on a Stipulation and Agreement of Settlement filed on August 15, 2025. This approach channels the dispute through internal governance mechanisms and court review rather than a trial.

If the Court approves the Stipulation, insurance carriers would pay Cencora $111.3 million, reduced by any attorneys’ fees and litigation expenses the Court awards to plaintiffs’ counsel. The company states that defendants make no admission of liability and expressly deny wrongdoing, which is typical for this type of resolution. Investors can track progress through the court’s approval process and the settlement documents and notice posted on the Investor Relations section of the company’s website as referenced in the disclosure.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What legal matter does Cencora (COR) describe in this 8-K?

The company discusses a stockholder derivative action in the Delaware Court of Chancery titled Lebanon County Employees’ Retirement Fund v. Steven H. Collis et al., C.A. No. 2021-1118-JTL, alleging breaches of fiduciary duty related to oversight of its controlled substance diversion control programs.

What is the proposed financial impact of the Cencora (COR) derivative settlement?

If the Court approves the Stipulation and Agreement of Settlement, insurance carriers would pay $111.3 million to Cencora, less any attorneys’ fees and litigation expenses the Court awards to plaintiffs’ counsel.

Does Cencora admit wrongdoing in the proposed settlement of the derivative action?

No. The disclosure states that the Stipulation does not include any admission of liability and that the defendants expressly deny any wrongdoing in connection with the claims.

What role did the Special Litigation Committee play in Cencora’s (COR) case?

On January 12, 2024, the Board created a Special Litigation Committee and delegated full authority over the litigation to it. The Court then stayed the action while the committee investigated, and the settlement in principle followed a mediation conducted on June 24, 2025.

Where can investors find the Cencora (COR) settlement documents and notice?

Copies of the Stipulation and Agreement of Settlement, Compromise, and Release and the Notice of Pendency and Proposed Settlement of Stockholder Derivative Action, Settlement Hearing, and Right to Appear are filed as Exhibits 99.1 and 99.2 and are also available on the Investor Relations section of Cencora’s website at https://investor.cencora.com.

What did the Court direct Cencora (COR) to do in its scheduling order?

On August 19, 2025, the Court entered a Scheduling Order directing Cencora to file this report with the SEC with copies of the Stipulation and the Notice as exhibits and to post those documents on the Investor Relations section of its website.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/03/2025 - 04:43 PM Learn about SEC filing dates

false 0001140859 0001140859 2025-09-03 2025-09-03 0001140859 us-gaap:CommonStockMember 2025-09-03 2025-09-03 0001140859 COR:Sec2.875SeniorNotesDue2028Member 2025-09-03 2025-09-03 0001140859 COR:Sec3.625SeniorNotesDue2032Member 2025-09-03 2025-09-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 3, 2025

Cencora, Inc.

(Exact name of registrant as specified in its charter)

Commission File Number: 1-16671

Delaware		23-3079390
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

1 West First Avenue Conshohocken, PA		19428-1800
(Address of principal executive offices)		(Zip Code)

(610) 727-7000

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of exchange on which registered
Common Stock	COR	New York Stock Exchange (NYSE)
2.875% Senior Notes due 2028	COR28	New York Stock Exchange (NYSE)
3.625% Senior Notes due 2032	COR32	New York Stock Exchange (NYSE)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01 Other Events.

On September 3, 2025, Cencora, Inc., a Delaware corporation (the “Company”), announced an agreement, subject to court approval, that would resolve the stockholder derivative action captioned Lebanon County Employees’ Retirement Fund v. Steven H. Collis et al., C.A. No. 2021-1118-JTL (the “Action”).

As the Company has previously disclosed, on December 30, 2021, the Lebanon County Employees’ Retirement Fund and Teamsters Local 443 Health Services & Insurance Plan (the “Plaintiffs”) filed a complaint for the Action in the Court of Chancery of the State of Delaware (the “Court”) against the Company and certain of its officers and members of its Board of Directors (the “Board”). The complaint alleges claims for breach of fiduciary duty allegedly arising from the Board’s and certain officers’ oversight of the Company’s controlled substance diversion control programs. On January 12, 2024, the Board established a Special Litigation Committee (the “SLC”) and delegated to the SLC the Board’s full authority with respect to the litigation. On March 4, 2024, the Court granted the SLC’s consented-to motion to stay the Action pending its investigation of the allegations within the complaint. On July 28, 2025, the SLC notified the Court that the parties had reached an agreement in principle to settle all claims in the Action following a successful mediation conducted on June 24, 2025, and filed a stipulation to stay the Action pending the presentation of a stipulation of settlement for the Court's approval. The Court granted the stipulation staying the Action on July 29, 2025.

On August 15, 2025, the parties to the Action filed a Stipulation and Agreement of Settlement, Compromise, and Release to the Court (the “Stipulation”) that would resolve the Action. If the Court approves the Stipulation, insurance carriers would pay the Company $111.3 million, less any attorneys’ fees and litigation expenses awarded by the Court to Plaintiffs’ counsel. The Stipulation does not include any admission of liability, and the defendants expressly deny any wrongdoing.

On August 19, 2025, the Court entered a Scheduling Order in the Action directing the Company (i) to file this Current Report on Form 8-K with the Securities and Exchange Commission with copies of the Stipulation and the Notice of Pendency and Proposed Settlement of Stockholder Derivative Action, Settlement Hearing, and Right to Appear (the “Notice”) filed as exhibits hereto, and (ii) to post a copy of the Stipulation and the Notice on the “Investor Relations” section of the Company’s website.

Copies of the Stipulation and the Notice are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference. The Stipulation and the Notice are also available on the Investor Relations section of the Company’s website at https://investor.cencora.com.

Item 9.01 Financial Statements and Exhibits.

(d)         Exhibits.

Exhibit No.		Description
99.1		Stipulation and Agreement of Settlement, Compromise, and Release
99.2		Notice of Pendency and Proposed Settlement of Stockholder Derivative Action, Settlement Hearing, and Right to Appear
104		Cover Page Interactive Data File (formatted as inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Cencora, Inc.
September 3, 2025	By:	/s/ Elizabeth S. Campbell
		Name: Elizabeth S. Campbell
		Title: Executive Vice President and Chief Legal Officer